BRCA2 and pancreatic neoplasm: We also obtained similar results using the BRCA2-deficient pancreatic cancer cell line CAPAN1 and its BRCA2-revertant CAPAN1(C2-1) (Figure 4(b), surviving fraction at 5 nM gemcitabine: 0.229±0.011 for CAPAN1 and 0.091±0.011 for CAPAN1(C2-1), p<0.05, and at 25 nM gemcitabine: 0.051 ± 0.011 for CAPAN1 and 0.013 ± 0.009 for CAPAN1(C2-1), p<0.05).